Clinical-stage biopharma Alumis Inc. (ALMS) is gaining significant Wall Street attention after its lead drug candidate, envudeucitinib, successfully met all endpoints in key Phase 3 trials for plaque psoriasis, prompting multiple analyst upgrades and optimistic price targets.
Sanofi reports a pivotal Phase 3 win for its investigational therapy venglustat in a rare neurological disorder, alongside positive EU regulatory news for Rezurock and progress for amlitelimab, signaling a strategic shift toward high-value specialty medicines.
Citizens reiterates a 'Market Outperform' rating and $396 price target for BeOne Medicines (ONC), driven by robust Phase 3 trial results in gastric cancer. The firm highlights the company's strong pipeline and cash position as key growth drivers.
Immunocore Holdings (NASDAQ: IMCR) has drawn renewed bullish sentiment from analysts at H.C. Wainwright and UBS, who highlight the stock's potential as key Phase 3 trial data for its cancer immunotherapies approaches later this decade.
CSW Industrials reports historic revenue following three strategic acquisitions, including its largest ever. However, integration costs and rising interest expenses pressure margins, leading the firm to miss earnings expectations as its stock faces recent headwinds.
H.C. Wainwright has trimmed its price target on Genmab following mixed Phase 3 results for its lymphoma drug EPKINLY, though maintains a Buy rating, citing precedent and ongoing trials.
Footwear giant Deckers Brands announced a 7.1% rise in Q3 FY26 net sales to $1.95 billion, driven by explosive growth from its HOKA running brand and solid gains from UGG, despite a challenging retail environment.
TreeHouse Foods (THS) shares have rebounded sharply over the past three months, gaining 31%, even as the company reports significant annual losses. This divergence between short-term momentum and long-term fundamentals is prompting a fresh debate on valuation and the path to profitability for the private-label food manufacturer.
Enphase Energy, a key player in the home energy management sector, is set to release its quarterly earnings after the bell on Tuesday. Investors are watching closely as the company navigates a shifting market landscape.
A wave of token unlocks valued at over $638 million is set to hit the cryptocurrency market this week, adding selling pressure to an already struggling altcoin sector facing thin liquidity and weak investor demand.
Pharmaceutical giant Eli Lilly announces a major $3.5 billion manufacturing expansion for its weight-loss drugs and enters two strategic research collaborations in gene editing and immunology, signaling aggressive growth plans amid a recent stock valuation dip.
Alibaba Group has pledged 3 billion yuan ($431 million) to promote its Qwen AI app during the upcoming Lunar New Year holiday, significantly outpacing similar campaigns by rivals Tencent and Baidu and marking a major escalation in China's competitive AI landscape.
As diplomatic efforts to secure a ceasefire in Gaza show fragile progress, Israeli airstrikes have resulted in the deaths of at least 30 Palestinians overnight, with multiple children among the casualties, according to local health authorities.
Despite a stellar 38% gain over the past year, analysis suggests Federated Hermes (NYSE: FHI) shares may still be trading at a discount to their intrinsic value, presenting a potential opportunity in the capital markets sector.
After the COVID-19 windfall subsided, Pfizer CEO Albert Bourla is steering the pharmaceutical giant into a high-stakes, $23 billion pivot to cancer research. Facing a looming patent cliff and plummeting vaccine revenue, Bourla is betting on scientific innovation to secure the company's future—and redefine cancer treatment.
Pharmaceutical giant Eli Lilly announces a massive $3.5 billion investment in a new Pennsylvania manufacturing facility, aiming to scale up production of its blockbuster weight-loss therapies like retatrutide amid soaring global demand.
Analyst Tara Bancroft of TD Cowen lowered the firm's price target on Geron Corporation (GERN) from $4 to $3, maintaining a Buy rating ahead of the biotech's fourth-quarter results. The move reflects a model update as the company navigates mixed commercial progress for its blood cancer drug RYTELO.
The commencement of sea trials for the nuclear-powered aircraft carrier USS John F. Kennedy coincides with the 140th anniversary of its builder, Newport News Shipbuilding, underscoring Huntington Ingalls Industries' entrenched role in U.S. naval defense and its long-term investment profile.
Enphase Energy unveils a strategic restructuring involving workforce reductions and a new home battery partnership, as the solar technology firm navigates a challenging market and mixed investor returns.
A blistering rally in gold and silver came to an abrupt halt Friday, with prices tumbling sharply as market volatility surged and analysts warned the historic run may be entering a precarious phase.
